Skip to main content

ALK-Abelló

ALK-Abello A/S is a Danish pharmaceutical company specializing in allergy immunotherapy and allergy prevention. The company researches, produces, and commercializes sublingual and subcutaneous allergy vaccines, sublingual allergy immunotherapy tablets, and emergency adrenaline auto-injectors. Main revenue drivers include global commercial sales of allergy tablets for house dust mite, grass, and tree pollen allergies alongside emergency adrenaline treatments. ALK-Abello serves allergy specialists, ENT doctors, clinical immunologists, and allergic patients across Europe, North America, and Asia-Pacific. The company holds a world-leading market position as the global leader in allergy immunotherapy treatments. Headquartered in Horsholm, Denmark, ALK-Abello A/S is listed on Nasdaq Copenhagen.

38 of the funds FundTelligence covers report a position in ALK-Abelló.

Sector
Health Care
Country
Denmark
Funds holding it
38

Funds holding ALK-Abelló

Showing the 8 largest of 38 funds holding it.

Loading...